The recommended dose is 2 mg aflibercept (0.05 mL). Eylea is given as an injection into your eye (intravitreal injection). Posology wet AMD The recommended dose for Eylea is 2 mg aflibercept, equivalent to 0.05 mL. Eylea treatment is initiated with one injection per month for three consecutive doses. The treatment interval is then extended to two months. Based on the physician's judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at two months or further extended using a treat-and-extend dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. There is no requirement for monitoring between injections. Based on the physician's judgement the schedule of monitoring visits may be more frequent than the injection visits. Macular oedema secondary to RVO (branch RVO or central RVO) The recommended dose for Eylea is 2 mg aflibercept equivalent to 0.05 mL. After the initial injection, treatment is given monthly. The interval between two doses should not be shorter than one month. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Eylea should be discontinued. Monthly treatment continues until maximum visual acuity is achieved and/or there are no signs of disease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat-and-extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes, however there are insufficient data to conclude on the length of these intervals. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. The monitoring and treatment schedule should be determined by the treating physician based on the individual patient's response. Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography). Diabetic macular oedema The recommended dose for Eylea is 2 mg aflibercept equivalent to 0.05 mL. Eylea treatment is initiated with one injection per month for five consecutive doses, followed by one injection every two months. Based on the physician's judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at 2 months or individualized, such as with a treat-and-extend dosing regimen, where the treatment intervals are usually increased by 2-week increments to maintain stable visual and/or anatomic outcomes. There are limited data for treatment intervals longer than 4 months. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. Treatment intervals shorter than 4 weeks have not been studied. The schedule for monitoring should be determined by the treating physician. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Eylea should be discontinued. Myopic choroidal neovascularisation The recommended dose for Eylea is a single intravitreal injection of 2 mg aflibercept equivalent to 0.05 mL. Additional doses may be administered if visual and/or anatomic outcomes indicate that the disease persists. Recurrences should be treated as a new manifestation of the disease. The schedule for monitoring should be determined by the treating physician. The interval between two doses should not be shorter than one month. Special populations Hepatic and/or renal impairment No specific studies in patients with hepatic and/or renal impairment have been conducted with Eylea. Available data do not suggest a need for a dose adjustment with Eylea in these patients. Elderly population No special considerations are needed. There is limited experience in patients older than 75 years with DME. Paediatric population The safety and efficacy of Eylea have not been established in children and adolescents. There is no relevant use of Eylea in the paediatric population for the indications of wet AMD, CRVO, BRVO, DME and myopic CNV. PREGNANCY AND LACTATION Eylea should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus. As a precautionary measure, breast-feeding is not recommended during the use of Eylea. SIDE EFFECTS Detachment of the retinal pigment epithelium, Retinal degeneration, Vitreous haemorrhage, Cataract cortical, Cataract nuclear, Cataract subcapsular, Corneal erosion, Corneal abrasion, Intraocular pressure increased, Vision blurred ACTIVE INGREDIENT aflibercept